ArticleFrontiers in microbiology2019
Colistin Combined With Tigecycline: A Promising Alternative Strategy to Combat
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Effect of antibiotic regimens for bloodstream infections caused by KPC-producing enterobacter: a network meta-analysis.Frontiers in medicine · 2026Pooled it
- The rise of ultrashort cationic β-peptides as promising antimicrobial therapeutics.RSC medicinal chemistry · 2025Review
- Heteroresistance is associated with mutations during low concentration of tigecycline therapy in multiple-resistant Klebsiella pneumoniae.Annals of clinical microbiology and antimicrobials · 2025Article
- Assessment of the Last-Resort Antibiotics against Extended Spectrum Beta-Lactamase/Carbapenemase and Biofilm ProducerArchives of Razi Institute · 2025Article
- Regional insights on the prevalence and antimicrobial susceptibility pattern of carbapenem and colistin-resistant gram-negative bacteria: an observational cross-sectional study from Karachi, Pakistan.BMC infectious diseases · 2025Observational
- Bactericidal versus bacteriostatic antibacterials: clinical significance, differences and synergistic potential in clinical practice.The Journal of antimicrobial chemotherapy · 2025Review
- Boosting the Antibacterial Activity of Azithromycin on Multidrug-ResistantInternational journal of molecular sciences · 2023Article
- Phentolamine Significantly Enhances Macrolide Antibiotic Antibacterial Activity against MDR Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2023Article
- Whole-genome sequence analysis of clinically isolated carbapenem resistant Escherichia coli from Iran.BMC microbiology · 2023Article
- Synergistic Activity of Tetrandrine and Colistin againstAntibiotics (Basel, Switzerland) · 2022Article
- Silver Nanoparticles and Its Mechanistic Insight for Chronic Wound Healing: Review on Recent Progress.Molecules (Basel, Switzerland) · 2022Review
- Recent Advances in the Use of Molecular Methods for the Diagnosis of Bacterial Infections.Pathogens (Basel, Switzerland) · 2022Review
- Dissemination and prevalence of plasmid-mediated high-level tigecycline resistance geneFrontiers in microbiology · 2022Review
- Pharmacodynamic Target Assessment and PK/PD Cutoff Determination for Gamithromycin AgainstFrontiers in veterinary science · 2022Article
- The burden of carbapenem-resistantFrontiers in pharmacology · 2022Article
- Discerning the role of polymyxin B nonapeptide in restoring the antibacterial activity of azithromycin against antibiotic-resistantFrontiers in microbiology · 2022Article
- Clinical Efficacy and Nephrotoxicity of the Loading Dose Colistin for the Treatment of Carbapenem-ResistantPharmaceutics · 2021Article
- Comparison of Bleeding Risk Between Colistin-Tigecycline and Colistin-Carbapenem Treatment Regimens: A Retrospective Cohort Study.Infection and drug resistance · 2021Article
- Current Update on Intrinsic and Acquired Colistin Resistance Mechanisms in Bacteria.Frontiers in medicine · 2021Review
- Activity of Tigecycline or Colistin in Combination with Zidovudine against Escherichia coli HarboringAntimicrobial agents and chemotherapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections due to carbapenem-resistant NDM-producing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.